Abstract
The activation of cavernous local renin-angiotensin system has an important role in pathogenesis of diabetic erectile dysfunction (ED). In our primary study, we found that angiotensin Type 1 receptor blocker improved the erectile function of diabetic rats. Therefore we explored the losartan in clinical treatment for diabetic patients suffering with ED. A total of 124 diabetic patients with ED were included in this study and treated with losartan or tadalafil or losartan plus tadalafil or watch for waiting as control for 12 weeks. Erectile function was assessed by International Index of Erectile Function (IIEF-5) questionnaire, the percentage of positive responses to sexual encounter profile questions 2 (SEP2), 3 (SEP3) and the global assessment question (GAQ). Losartan or tadalafil or losartan plus tadalafil significantly improved the mean IIEF-5 scores, the percentage of successful penetrations (SEP2), the successful intercourse completions (SEP3) and GAQ (P<0.05). The combination of losartan and tadalafil is more effective than the single-use of losartan or tadalafil (P<0.05). The patients with moderate and mild ED had better response rates to losartan than patients with severe ED. This is the first clinical trial in losartan therapy on diabetic patients suffering from ED. Losartan seems to be effective and well-tolerated in diabetic ED patients, especially for mild to moderate ones. The combination therapy of losartan and tadalafil appeared to be more effective than monotherapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 8 print issues and online access
$259.00 per year
only $32.38 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Chen Y, Dai Y, Wang R . Treatment strategies for diabetic patients suffering from erectile dysfunction. Expert Opin Pharmacother 2008; 9: 257–266.
Moore CR, Wang R . Pathophysiology and treatment of diabetic erectile dysfunction. Asian J Androl 2006; 8: 675–684.
Israilov S, Shmuely J, Niv E, Engelstein D, Livne P, Boniel J . Evaluation of a progressive treatment program for erectile dysfunction in patients with diabetes mellitus. Int J Impot Res 2005; 17: 431–436.
Behrend L, Vibe-Petersen J, Perrild H . Sildenafil in the treatment of erectile dysfunction in men with diabetes: demand, efficacy and patient satisfaction. Int J Impot Res 2005; 17: 264–269.
Blonde L . Sildenafil citrate for erectile dysfunction in men with diabetes and cardiovascular risk factors: a retrospective analysis of pooled data from placebo-controlled trials. Curr Med Res Opin 2006; 22: 2111–2120.
Chen Y, Li SX, Yao LS, Wang R, Dai YT . Valsartan treatment reverses erectile dysfunction in diabetic rats. Int J Impot Res 2007; 19: 366–370.
Kifor I, Williams GH, Vickers MA, Sullivan MP, Jodbert P, Dluhy RG . Tissue angiotensin II as a modulator of erectile function. I. Angiotensin peptide content, secretion and effects in the corpus cavernosum. J Urol 1997; 157: 1920–1925.
Yang R, Yang B, Wen Y, Fang F, Cui S, Lin G et al. Losartan, an angiotensin type I receptor, restores erectile function by downregulation of cavernous renin-angiotensin system in streptozocin-induced diabetic rats. J Sex Med 2009; 6: 696–707.
Ertemi H, Mumtaz FH, Howie AJ, Mikhailidis DP, Thompson CS . Effect of angiotensin II and its receptor antagonists on human corpus cavernous contractility and oxidative stress: modulation of nitric oxide mediated relaxation. J Urol 2011; 185: 2414–2420.
Abdel Aziz MT, El Asmer MF, Mostafa T, Atta H, Mahfouz S, Fouad H et al. Effects of losartan, HO-1 inducers or HO-1 inhibitors on erectile signaling in diabetic rats. J Sex Med 2009; 6: 3254–3264.
Llisterri JL, Lozano Vidal JV, Argaya Roca M, Pol Bravo C, Sanchez Zamorano MA . Sexual dysfunction in hypertensive patients treated with losartan. Am J Med Sci 2001; 321: 336–341.
Düsing R . Effect of the angiotensin II antagonist valsartan on sexual function in hypertensive men. Blood Press Suppl 2003; 2: 29–34.
Baumhäkel M, Schlimmer N, Böhm M . Effect of irbesartan on erectile function in patients with hypertension and metabolic syndrome. Int J Impot Res 2008; 20: 493–500.
Montorsi F, Verheyden B, Meuleman E, Jünemann KP, Moncada I, Valiquette L et al. Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction. Eur Urol 2004; 45: 339–344, discussion 344-345.
Porst H, Giuliano F, Glina S, Ralph D, Casabé AR, Elion-Mboussa A et al. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5 mg and 10 mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol 2006; 50: 351–359.
Porst H, Glina S, Ralph D, Zeigler H, Wong DG, Woodward B . Durability of response following cessation of tadalafil taken once daily as treatment for erectile dysfunction. J Sex Med 2010; 7: 3487–3494.
Liau CS, Lee CM, Sheu SH, Ueng KC, Chien KL, Su TC et al. Efficacy and safety of olmesartan in the treatment of mild-to-moderate essential Hypertension in chinese patients. Clin Drug Investig 2005; 25: 473–479.
Fusco F, Razzoli E, Imbimbo C, Rossi A, Verze P, Mirone V . A new era in the treatment of erectile dysfunction: chronic phosphodiesterase type 5 inhibition. BJU Int 2010; 105: 1634–1639.
De Young LX, Domes T, Lim K, Carson J, Brock GB . Endothelial rehabilitation: the impact of chronic PDE5 inhibitors on erectile function and protein alterations in cavernous tissue of diabetic rats. Eur Urol 2008; 54: 213–220.
Kovanecz I, Rambhatla A, Ferrini MG, Vernet D, Sanchez S, Rajfer J et al. Chronic daily tadalafil prevents the corporal fibrosis and veno-occlusive dysfunction that occurs after cavernosal nerve resection. BJU Int 2008; 101: 203–210.
Acknowledgements
This study was supported by National Natural Science Foundation of China (30772175) (30801143) and the Jiangsu Government Scholarship for Overseas Studies and Nanjing Medical Science and technique Development Foundation.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Chen, Y., Cui, S., Lin, H. et al. Losartan improves erectile dysfunction in diabetic patients: a clinical trial. Int J Impot Res 24, 217–220 (2012). https://doi.org/10.1038/ijir.2012.4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ijir.2012.4